Abstract
BackgroundThe optimal dosages, timing, and treatment sequencing for standard-of-care neoadjuvant chemoradiotherapy necessitate re-evaluation when used in conjunction with immune checkpoint inhibitors for patients with resectable, locally advanced esophageal squamous cell...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have